Immunic, Inc.

IMUX

$14.80

$-0.01 (-0.07%)

Closed

Loading chart...

IndexN/A

Market Cap0.15B

Enterprise Value0.07B

Income$-0.03B

Sales$0.00B

EmployeesN/A

P/E-5.67

P/SN/A

P/B-12.46

P/C-0.97

EV/EBITDA-0.70

EV/SalesN/A

EPS (ttm)-2.61

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume0.13M

Shs Outstand0.01B

Change-0.07%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Jun 1006:30AMImmunic to Participate in Investor, Industry and Scientific Conferences in June(prnewswire.com)

May 2907:01AMAs SpaceX reportedly snips IPO valuation, prediction markets are still saying it will be a $2 trillion company(proactiveinvestors.com)

May 2810:30AMImmunic presents new vidofludimus calcium data at multiple sclerosis conference(proactiveinvestors.com)06:30AMImmunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Insider Trading

View All

Insider

Type

Price

Value

Date

BONNEY MICHAEL W

Award

100.0K

$12.08

$1.2M

Jun 29, 26

Vitt Daniel

Award

445.0K

$11.60

$5.2M

Jun 29, 26

Whaley Glenn

Award

120.0K

$11.60

$1.4M

Jun 29, 26

Tardio Jason

Award

253.0K

$11.60

$2.9M

Jun 29, 26

PHILLIPS BARCLAY A

Award

25.4K

$10.90

$277K

Jun 29, 26

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.

CEO: Daniel VittEmployees: 91www.immunic-therapeutics.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$50.00K	$15.00K	$998.00K
Gross Profit	N/A	N/A	N/A	N/A	N/A	$-50.00K	$-15.00K	$-998.00K
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$98.05M	$99.22M	$119.49M	$91.67M	$48.97M	$36.98M	$42.01M	$51.66M
Operating Income	$-98.05M	$-99.22M	$-119.49M	$-91.67M	$-48.97M	$-37.03M	$-42.02M	$-52.66M
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-100.51M	$-93.61M	$-120.41M	$-92.94M	$-44.02M	$-34.83M	$-41.48M	$-52.08M
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-1.00	$-2.11	$-3.78	$-3.92	$-2.81	$-4.51	$-39.16	$-52.26
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Immunic, Inc.

Insider Trading

Discover more